Risvodetinib for Parkinson’s: End of Phase 2 FDA Meeting Details Announced
ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...
Summit Max Trial Shows Highest First Pass Effect in Stroke Thrombectomy
Route 92 Medical announced positive results from its SUMMIT MAX trial of the HiPoint Reperfusion System, including the super-bore...
Microglia-Driven Inflammation: Key to Parkinson’s and Alzheimer’s?
ZyVersa Therapeutics announced new research supporting the potential of its Inflammasome ASC Inhibitor IC 100 as a disease-modifying treatment...
Galimedix Publishes Groundbreaking Alzheimer’s Data
Galimedix Therapeutics announced published preclinical data on GAL-201, a small molecule drug candidate for Alzheimer’s disease. The data demonstrates...
Tango Tx Doses First Patient in TNG456 Glioblastoma Trial
Tango Therapeutics has initiated a Phase 1/2 clinical trial of TNG456, a brain-penetrant PRMT5 inhibitor, for patients with MTAP-deleted...
Tonix Doses First Patient in Phase 2 OASIS Study of TNX-102 SL
Tonix Pharmaceuticals has initiated a Phase 2 trial, called OASIS, to evaluate TNX-102 SL for reducing the severity of...
Regeneron Acquires 23andMe in Court-Supervised Sale
23andMe, a consumer genetics and biotechnology company, has entered into a definitive agreement to be acquired by Regeneron Pharmaceuticals...
Exact Therapeutics Announces Positive Results from Activate Trial
EXACT Therapeutics announced positive final data from its Phase 1 ACTIVATE trial, demonstrating that Acoustic Cluster Therapy (ACT) significantly...
CRISPR & Sirius Therapeutics Announce Novel siRNA Therapies
CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting siRNA therapy for thromboembolic disorders....
Serum TTR Levels Predict Improved Survival in ATTR-CM Study
BridgeBio Pharma released data from its Phase 3 ATTRibute-CM trial of acoramidis, showing a link between early, sustained increases...